Drug Profile
Tc 99m nofetumomab merpentan
Alternative Names: F(ab)2 NRLU10 technetium (Tc 99m); OncoTrac; OncoTrac NSCLC; OncoTrac SCLC; Technetium Tc 99m-nofetumomab merpentan; VerLumaLatest Information Update: 21 Jun 2006
Price :
$50
*
At a glance
- Originator Poniard Pharmaceuticals
- Class Monoclonal antibodies; Monoclonal antibody diagnostics; Organotechnetium compounds; Radiopharmaceuticals; Technetium compounds
- Mechanism of Action Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Non-small cell lung cancer; Small cell lung cancer
Most Recent Events
- 21 Jun 2006 NeoRx Corporation is now called Poniard Pharmaceuticals Inc.
- 22 May 1997 Launched for Small cell and Non-small cell lung cancer diagnosis in USA (IV)
- 12 Feb 1997 Registered for Small cell and Non-small cell lung cancer diagnosis in USA (IV)